Results 91 to 100 of about 9,130,139 (414)

Mitochondria in Huntington's disease

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
Huntington's disease (HD) is an inherited progressive neurodegenerative disorder associated with involuntary abnormal movements (chorea), cognitive deficits and psychiatric disturbances. The disease is caused by an abnormal expansion of a CAG repeat located in exon 1 of the gene encoding the huntingtin protein (Htt) that confers a toxic function to the
Maria Damiano, Laurie Galvan, Laurie Galvan, Nicole Déglon, Nicole Déglon, Emmanuel Brouillet, Emmanuel Brouillet   +6 more
openaire   +7 more sources

Listerin Alleviates Alzheimer's Disease through IRE1‐mediated Decay of TLR4 mRNA

Advanced Science, EarlyView.
Alzheimer's disease (AD) progression is influenced by microglia‐mediated neuroinflammation. Here, it is demonstrated that Listerin suppresses neuroinflammatory signaling and cognitive impairment in AD models by triggering IRE1α‐mediated TLR4 mRNA decay. Adenoviral Listerin delivery reduces amyloid‐β pathology, positioning it as a new therapeutic target.
Fei Qin, Runyu Cao, Xuemei Bai, Jiahua Yuan, Wanwei Sun, Yi Zheng, Xiaopeng Qi, Wei Zhao, Bingyu Liu, Chengjiang Gao   +9 more
wiley   +1 more source

Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease

Nature Communications, 2019
Huntington’s disease (HD) is a neurodegenerative disorder that manifests with movement dysfunction. The expression of mutant Huntingtin (mHTT) disrupts the functions of brain cells.
Jian-Jing Siew, Hui-Mei Chen, Huan-Yuan Chen, Hung-Lin Chen, C. Chen, B. Soong, Yih-Ru Wu, Ching-Pang Chang, Yi-Chen Chan, Chun-Hung Lin, Fu-Tong Liu, Y. Chern   +11 more
semanticscholar   +1 more source

Progression of motor subtypes in Huntington’s disease. a 6-year follow-up study [PDF]

, 2016
The objective of this study is to investigate the progression of predominantly choreatic and hypokinetic-rigid signs in Huntington's disease (HD) and their relationship with cognitive and general functioning over time.
Bentivoglio, A. R., Burgunder, J. M., Craufurd, D., Ferraldeschi, Michela, Hart, E. P., Jacobs, M, Reilmann, R., Ristori, Giovanni, Romano, Silvia, Roos, R. A. C., Saft, C., The REGISTRY, investigators of the European Huntington’s Disease Network, van Zwet, E. W.   +12 more
core   +2 more sources

Explainable Deep Multilevel Attention Learning for Predicting Protein Carbonylation Sites

Advanced Science, EarlyView.
Selective carbonylation sites (SCANS) are conceptualized, designed, evaluated, and released. SCANS captures segment‐level, protein‐level, and residue embeddings features. It utilizes elaborate loss function to penalize cross‐predictions at the residue level.
Jian Zhang, Jingjing Qian, Pei Wang, Xuan Liu, Fuhao Zhang, Haiting Chai, Quan Zou   +6 more
wiley   +1 more source

Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington’s disease

Drug Design, Development and Therapy, 2016
Yixuan Zeng,1,2,* Wenyuan Guo,1,* Guangqing Xu,3 Qinmei Wang,4 Luyang Feng,1,2 Simei Long,1 Fengyin Liang,1 Yi Huang,1 Xilin Lu,1 Shichang Li,5 Jiebin Zhou,5 Jean-Marc Burgunder,6 Jiyan Pang,5 Zhong Pei1,2 1Department of Neurology, National Key Clinical
Zeng YX, Guo WY, Xu GQ, Wang QM, Feng LY, Long SM, Liang FY, Huang Y, Lu XL, Li SC, Zhou JB, Burgunder JM, Pang JY, Pei Z   +13 more
doaj  

The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis

Drug Delivery, 2018
Neurodegenerative movement disorders mainly include Parkinson’s disease, atypical parkinsonisms, Huntington disease, and hereditary ataxia. Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis.
Jia Liu, Lu-Ning Wang
doaj   +1 more source

Time series analysis of Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis [PDF]

arXiv, 2013
The aim of this paper is to study the (clinical) time-series data of three diseases with complex dynamics: Parkinson's disease, Huntington's disease and Amyotrophic Lateral Sclerosis. For this purpose, first all of the time series data are embedded in a vector space of suitable dimension and then the correlation dimension of the above mentioned ...
arxiv  

International Guidelines for the Treatment of Huntington's Disease

Frontiers in Neurology, 2019
The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to
A. Bachoud-Lévi, J. Ferreira, R. Massart, K. Youssov, A. Rosser, M. Busse, D. Craufurd, R. Reilmann, G. De Michele, D. Rae, F. Squitieri, K. Seppi, Charles Perrine, C. Scherer-Gagou, O. Audrey, C. Verny, J. Burgunder   +16 more
semanticscholar   +1 more source

Transient Interdomain Interactions Modulate the Monomeric Structural Ensemble and Self‐Assembly of Huntingtin Exon 1

Advanced Science, EarlyView.
Polyglutamine (polyQ) tract expansion (≥ 36 amino acids) within the N‐terminal region of the Huntingtin protein (Httex1) causes Huntington's disease (HD), for which the underlying causes are not well‐understood. The authors performed computer simulations to understand the cause of HD at the molecular level.
Priyesh Mohanty, Tien Minh Phan, Jeetain Mittal   +2 more
wiley   +1 more source